Duration of Androgen Deprivation Therapy in High-risk Prostate Cancer: A Randomized Phase III Trial

A Proportional Hazards Model for the Subdistribution of a Competing Risk

Jason P. Fine · Journal of the American Statistical Association · 1999 · 13.6K citations

Public Health, Biostatistics, Cost-effectiveness Analysis +15

A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk

The Annals of Statistics · 1988 · 5K citations · Full text

Public Health, Biostatistics, Risk Analysis +15

Interpreting the significance of changes in health-related quality-of-life scores.

David Osoba, George Rodrigues, James D. Myles et al. · Journal of Clinical Oncology · 1998 · 2.9K citations

Pharmacy, Oncology, Health Assessment +16

Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and Goserelin

M. Bolla, Dionisio González, Padraig Warde et al. · New England Journal of Medicine · 1997 · 1.6K citations · Full text

Medicine, Oncology, Urology +15

Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy for Prostate Cancer

Nancy L. Keating, A. James O’Malley, Matthew R. Smith · Journal of Clinical Oncology · 2006 · 1.4K citations · Full text

Medicine, Endocrinology, Oncology +15